查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1544104

全球预测与预测测试市场

Predictive and Presymptomatic Testing
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 159 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球预测和预测测试市场将达到 104 亿美元

全球预测和预测测试市场预计 2023 年为 55 亿美元，预计到 2030 年将达到 104 亿美元，在 2023-2030 年分析期间复合年增长率为 9.5%。

美国市场预估成长14亿美元，中国复合年增长率12.6%

到 2023 年，美国预测和预测测试市场预计将达到 14 亿美元。中国作为世界第二大经济体，预计2030年市场规模将达24亿美元，2023-2030年分析期间复合年增长率为12.6%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 6.5% 和 7.5%。在欧洲，德国的复合年增长率预计为 7.4%。

全球预测测试和预测测试市场 - 主要趋势和驱动因素总结

预测和预测测试：预测健康风险

预测和预测测试使用基因和其他诊断测试来评估一个人在症状出现之前患某种特定疾病的风险。这些测试分析 DNA、蛋白质和其他生物标记物，以识别与癌症、心臟病和神经退化性疾病等疾病发生可能性增加相关的突变和其他指标。预测测试通常用于有特定疾病家族病史的人，以便进行早期疗育和预防措施，以降低风险或延迟发病。另一方面，症状前检测用于确定无症状性个体是否会患上已知在家族中遗传的遗传疾病。这些测试的主要目的是为个人和医疗保健提供者提供有价值的信息，以指南医疗决策和生活方式的改变，最终改善健康结果。

技术进步如何改进预测和预测测试？

技术的进步极大地提高了预测和预测测试的准确性、可访问性和范围。次世代定序仪(NGS) 的进步使得快速且经济高效地分析基因组的大片段成为可能，从而能够识别与疾病风险相关的更广泛的遗传变异。更敏感和特异性的生物标记的开发提高了我们甚至在症状出现之前检测疾病早期迹象的能力。此外，生物资讯学和机器学习演算法的整合增强了对遗传资料的解释，提供更准确的风险评估和个人化见解。此外，直接面向消费者的基因检测服务的兴起正在增加预测性检测的机会，使个人无需传统的临床环境即可了解自己的健康风险。这些技术改进扩大了预测和预测测试的用途和影响，使其成为主动医疗保健的宝贵工具。

预测和预测测试的主要用途和好处是什么？

预测和预测测试应用于医疗保健的各个领域，为加强疾病预防和控制提供了许多好处。在肿瘤学中，预测测试用于识别患有遗传性癌症的高风险个体，例如与乳癌和卵巢癌相关的 BRCA1/2 突变，从而可以进行早期监测和预防措施。在心臟病学中，基因检测可以识别与遗传性高胆固醇症等疾病相关的突变，并指导预防心臟病的干预措施。在神经病学中，无症状性检测对于亨廷顿舞蹈症等疾病有益，早期诊断有助于计划生育和生活方式选择。此外，药物基因组学中还使用预测测试来确定个体对特定药物的反应，从而製定个人化的治疗计划，以优化疗效并最大限度地减少副作用。预测和预测测试的主要好处包括能够在症状出现之前识别疾病风险，从而实现早期疗育、个人化医疗保健和改善患者治疗结果。透过提供对个人遗传倾向的宝贵见解，这些测试支持主动的健康管理和明智的决策。

推动预测测试和预测测试市场成长的因素有哪些？

预测测试和预测测试市场的成长是由多种因素推动的。人们对遗传学在疾病风险中的作用的认识不断提高以及对个人化医疗保健的需求不断增加是重要的驱动因素，因为这些测试为指导个体化治疗和预防策略提供了有价值的资讯。提高基因检测准确性、速度和可负担性的技术进步也推动了市场成长。直接面向消费者的基因检测服务的扩展，使这些检测更容易为大众所接受，进一步推动了需求。此外，对预防性医疗保健和早期疾病检测的更多关注有助于预测性和预测性测试的更广泛采用。人工智慧和生物资讯学等先进资料分析工具的整合正在提高这些测试的效用和准确性，推动其持续成长。这些因素，加上基因检测技术的持续创新，正在推动预测和预测测试市场的持续成长。

受访企业范例（14家知名企业）

  • 23andMe, Inc.
  • Abbott Molecular, Inc.
  • BioAxis DNA Research Centre Private Limited
  • Color Genomics, Inc.
  • Direct Laboratory Services LLC（DirectLabs）
  • Gene by Gene Ltd.
  • Genomic Diagnostics
  • Mapmygenome
  • Myriad Genetics, Inc.
  • Pathway Genomics Corporation
  • Positive Bioscience, Inc.
  • Quest Diagnostics, Inc.

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP14178

Global Predictive and Presymptomatic Testing Market to Reach US$10.4 Billion by 2030

The global market for Predictive and Presymptomatic Testing estimated at US$5.5 Billion in the year 2023, is expected to reach US$10.4 Billion by 2030, growing at a CAGR of 9.5% over the analysis period 2023-2030.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 12.6% CAGR

The Predictive and Presymptomatic Testing market in the U.S. is estimated at US$1.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 12.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.5% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR.

Global Predictive and Presymptomatic Testing Market - Key Trends and Drivers Summarized

Predictive and Presymptomatic Testing: Anticipating Health Risks

Predictive and presymptomatic testing involves the use of genetic and other diagnostic tests to assess an individual's risk of developing a particular disease before symptoms appear. These tests analyze DNA, proteins, and other biomarkers to identify mutations or other indicators that are associated with an increased likelihood of developing conditions such as cancer, heart disease, or neurodegenerative disorders. Predictive testing is typically used in individuals with a family history of a specific disease, allowing for early intervention and preventive measures that can reduce the risk or delay the onset of the disease. Presymptomatic testing, on the other hand, is used to determine whether an asymptomatic individual will develop a genetic disorder that is known to be present in the family. The primary purpose of these tests is to provide individuals and healthcare providers with valuable information that can guide medical decisions and lifestyle changes, ultimately improving health outcomes.

How Are Technological Advancements Enhancing Predictive and Presymptomatic Testing?

Technological advancements have significantly enhanced the accuracy, accessibility, and scope of predictive and presymptomatic testing. Advances in next-generation sequencing (NGS) have made it possible to analyze large segments of the genome quickly and cost-effectively, allowing for the identification of a broader range of genetic variants associated with disease risk. The development of more sensitive and specific biomarkers has improved the ability to detect early signs of disease, even before symptoms emerge. Additionally, the integration of bioinformatics and machine learning algorithms has enhanced the interpretation of genetic data, providing more accurate risk assessments and personalized insights. The rise of direct-to-consumer genetic testing services has also increased access to predictive testing, enabling individuals to gain insights into their health risks without the need for traditional clinical settings. These technological improvements have expanded the applications and impact of predictive and presymptomatic testing, making it a valuable tool for proactive healthcare.

What Are the Key Applications and Benefits of Predictive and Presymptomatic Testing?

Predictive and presymptomatic testing is applied in various areas of healthcare, offering numerous benefits that enhance disease prevention and management. In oncology, predictive testing is used to identify individuals at high risk of hereditary cancers, such as BRCA1/2 mutations associated with breast and ovarian cancer, enabling early surveillance and preventive measures. In cardiology, genetic testing can identify mutations linked to conditions like familial hypercholesterolemia, guiding interventions to prevent heart disease. Neurology benefits from presymptomatic testing for disorders such as Huntington's disease, where early diagnosis can inform family planning and lifestyle choices. Additionally, predictive testing is used in pharmacogenomics to determine how individuals will respond to specific medications, allowing for personalized treatment plans that optimize efficacy and minimize adverse effects. The primary benefits of predictive and presymptomatic testing include the ability to identify disease risks before symptoms appear, enabling early intervention, personalized healthcare, and improved patient outcomes. By providing valuable insights into an individual's genetic predispositions, these tests empower proactive health management and informed decision-making.

What Factors Are Driving the Growth in the Predictive and Presymptomatic Testing Market?

The growth in the predictive and presymptomatic testing market is driven by several factors. The increasing awareness of the role of genetics in disease risk and the growing demand for personalized healthcare are significant drivers, as these tests provide valuable information that can guide individualized treatment and prevention strategies. Technological advancements that enhance the accuracy, speed, and affordability of genetic testing are also propelling market growth. The expansion of direct-to-consumer genetic testing services, which make these tests more accessible to the general population, is further boosting demand. Additionally, the rising focus on preventive healthcare and the early detection of diseases are contributing to the increased adoption of predictive and presymptomatic testing. The integration of advanced data analysis tools, such as AI and bioinformatics, is enhancing the utility and accuracy of these tests, driving their continued growth. These factors, coupled with the ongoing innovation in genetic testing technologies, are driving the sustained growth of the predictive and presymptomatic testing market.

Select Competitors (Total 14 Featured) -

  • 23andMe, Inc.
  • Abbott Molecular, Inc.
  • BioAxis DNA Research Centre Private Limited
  • Color Genomics, Inc.
  • Direct Laboratory Services LLC (DirectLabs)
  • Gene by Gene Ltd.
  • Genomic Diagnostics
  • Mapmygenome
  • Myriad Genetics, Inc.
  • Pathway Genomics Corporation
  • Positive Bioscience, Inc.
  • Quest Diagnostics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Predictive and Presymptomatic Testing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Technological Advancements in Genetic Testing Propel Market Dynamics
    • Increasing Awareness of Preventive Healthcare Expands Addressable Market Opportunity
    • Government Initiatives for Genomic Research Strengthens Business Case
    • Growing Adoption of Direct-to-Consumer Genetic Tests Throws the Spotlight on Innovation
    • Focus on Early Disease Detection and Prevention Accelerates Market Demand
    • Expansion of Genetic Counseling Services Boosts Market Prospects
    • Rising Prevalence of Genetic Disorders Enhances Market Growth
    • Integration of AI and Big Data in Genetic Analysis Drives Market Dynamics
    • Increasing Investments in Genomic Research and Development Propels Market Expansion
    • Focus on Reducing Healthcare Costs Sustains Market Growth
    • Growing Use of Predictive Testing in Oncology Expands Market Reach
    • Focus on Regulatory Approvals and Reimbursement Policies Enhances Market Opportunities
    • Rising Consumer Interest in Ancestry and Health Insights Spurs Market Dynamics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Predictive and Presymptomatic Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Predictive and Presymptomatic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 5: USA Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 6: USA Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • CANADA
    • TABLE 7: Canada Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 8: Canada Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • JAPAN
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 9: Japan Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 10: Japan Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • CHINA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 11: China Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 12: China Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • EUROPE
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 13: Europe Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: Europe Historic Review for Predictive and Presymptomatic Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: Europe 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 16: France Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 17: France Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • GERMANY
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 18: Germany Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 19: Germany Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ITALY
    • TABLE 20: Italy Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Italy Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • UNITED KINGDOM
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 22: UK Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 23: UK Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SPAIN
    • TABLE 24: Spain Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Spain Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • RUSSIA
    • TABLE 26: Russia Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Russia Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF EUROPE
    • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Rest of Europe Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ASIA-PACIFIC
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 31: Asia-Pacific Historic Review for Predictive and Presymptomatic Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 32: Asia-Pacific 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 33: Australia Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 34: Australia Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • INDIA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 35: India Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: India Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SOUTH KOREA
    • TABLE 37: South Korea Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 38: South Korea Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF ASIA-PACIFIC
    • TABLE 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 40: Rest of Asia-Pacific Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • LATIN AMERICA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 41: Latin America Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: Latin America Historic Review for Predictive and Presymptomatic Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Latin America 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 44: Argentina Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Argentina Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • BRAZIL
    • TABLE 46: Brazil Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Brazil Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • MEXICO
    • TABLE 48: Mexico Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Mexico Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF LATIN AMERICA
    • TABLE 50: Rest of Latin America Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Latin America Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • MIDDLE EAST
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 52: Middle East Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 53: Middle East Historic Review for Predictive and Presymptomatic Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 54: Middle East 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 55: Iran Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 56: Iran Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ISRAEL
    • TABLE 57: Israel Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 58: Israel Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SAUDI ARABIA
    • TABLE 59: Saudi Arabia Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Saudi Arabia Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • UNITED ARAB EMIRATES
    • TABLE 61: UAE Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 62: UAE Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF MIDDLE EAST
    • TABLE 63: Rest of Middle East Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 64: Rest of Middle East Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • AFRICA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 65: Africa Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Africa Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR

IV. COMPETITION